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Summary Murine embryonal carcinoma cells, the pluripotent stem cells of teratocarcinoma were injected
simultaneously into caudal and cranial sities on the back of syngeneic recipients in order to determine
whether regional anatomical differences affect their take and growth rate and differentiation. The overall
tumour take rate was higher in caudal than cranial sites, but the initial weight of tumours was higher in the
cranial than caudal sites. Tumours developing in the two anatomical sites grew at the same rate with a linear
increase in volume. At the end of the 4-week experimental period the differences in the size of anterior and
posterior tumours were negligible and no histological differences were noted between the two groups. Our
data indicate that regional factors significantly affect the take rate and the the initial growth of this murine
teratocarcinoma, i.e. the establishment of solid tumours from injected stem cells. The growth rate of
established tumours was not affected by regional factors.
Human teratomas are a diverse group of tumours
originating in gonads and many other extragonadal
locations (O'Hare, 1978). Testicular tumours are
predominantly malignant (Pugh, 1976): the ovarian
are most benign (Scully, 1979), whereas, the
proportion of malignant and benign extragonadal
tumours varies from one site to another (O'Hare,
1978). Thus, most sacrococcygeal teratomas are
benign, for example, and most tumours of the
anterior mediastinum are malignant. The factors
determining and controlling the malignancy of
human teratomas are poorly understood, although,
by analogy with animal teratomas, one could
speculate that various anatomical, immunological,
endocrine and metabolic regulating mechanisms
could be involved (Solter & Damjanov, 1979).
Since teratomas produced from mouse embryos
represent an excellent replica of human neoplasia
(Solter & Damjanov, 1979), we have used a
transplantable, malignant murine teratoma
(henceforth referred to as "teratocarcinoma") to
study the possible effects of regional factors on
growth rate and malignant behaviour in this
tumour system.
Materials and methods
Tumours
All experiments were carried out with a new
pluripotent, slightly aneuploid mouse terato-
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carcinoma cell line (NF-1) that was recently
established in our laboratory from a
retransplantable BALB/c embryo-derived tumour
(Fox et al., submitted; Oosterhuis, 1983). The cells
are routinely grown in Falcon tissue culture flasks
in Dulbecco's modified Eagles medium (Gibco)
containing 15% foetal calf serum (FCS) (Gibco)
and antibiotics.
The tumour cells grown in vitro are adherent and
have the typical features of murine embryonal
carcinoma (EC) cells, the pluripotent stem cells of
teratocarcinoma (Martin & Evans, 1974). One
million cells injected s.c. into adult isogenic mice
produce solid tumours in 85-90% of animals. The
tumours consist of EC cells and various
differentiated tissues. The ratio of undifferentiated
and differentiated tissues is usually 2-3:1. The
tumour-bearing animals die 8-12 weeks after
inoculation of 106 cells and 6-10 weeks after
inoculation of 5 x 106 cells, due to progressive local
tumour growth. We never observed cessation of
tumour growth due to complete terminal
differentiation of tumour tissue.
Injection
Virgin, female BALB/c mice were obtained from
Jackson Laboratory, Bar Harbor, Maine. All the
experiments were performed on 6-8 week old
animals. The animals were anaesthetized with
Ketalar and the tumour cells were injected with a
26-gauge needle s.c. Tumour cell suspensions for
injection were prepared by trypsinization of
subconfluent cultures. They were resuspended in
medium containing FCS, then washed two times in
0.9 % saline and finally resuspended in 0.9 % saline
at concentrations of either 10 x 106 or 50 x 106
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cellsml-1. The tumour cell suspensions thus
prepared contained almost exclusively single cells
and were virtually 100 % viable. The volume of
injected fluid was always 0.1 ml per inoculum. Each
animal received two s.c. injections simultaneously,
each containing either 106 or 5 x 106 cells. The
injections were administered in the midline into the
tissue overlying the thoracic vertebra (cranial site)
or lumbar vertebra (caudal site) following the
protocol described in Auerbach et al. (1978c). The
take rate was determined at 4 time intervals and the
differences between the take in the caudal and
cranial location were determined by the log rank
test (Peto et al., 1977; Breslow, 1970).
Assessment oftumour growth
At predetermined time intervals following
inoculation, all the animals were anaesthesized and
palpated. Detected tumours were measured with a
caliper in 3 dimensions and the volume of the
tumour was determined according to the formula V
=d1xd2xd3xn/6. The formalin-fixed tumours in
the first experiment were also weighed after
removal of the surrounding non tumorous tissue.
The results were evaluated by means of Student t
test and the Pearson correlation coefficient test.
Histological examination
All tumours were fixed in formalin and examined
histologically in the plane of their largest diameter.
A semiquantitative assessment of their histological
features was made by roughly estimating the ratio
of fully differentiated tissues versus all other
"undifferentiated tissues" i.e. the EC cells, the loose
connective tissue stroma and all components that
could not be definitively identified as a distinct
somatic tissue. The components of the tumour were
considered as differentiated if displaying the typical
histological features of the following somatic tissues
that occur predictably in most solid tumours
produced by s.c. injection of the NF-1 cell line (Fox
et al., submitted): neural tissue, squamous
epithelium, glandular and ductal epithelium,
fibromuscular tissue, and cartilage (Figure 1).
Furthermore, morphometry was performed on all
tumours obtained by injecting 106 EC cells. To this
end the Merz Graticule was superimposed on each
tumour slide and 50-100 intersections were counted
at 25 x magnification to determine the exact
volume of differentiated somatic tissues. Areas
composed of necrotic tissue, which rarely exceeded
5 % of the total tumour volume were excluded
from the morphometric analysis. The morphometric
data were evaluated by the Student t test.
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Figure 1 Area in NF-1 transplantable terato-
carcinoma: well-differentiated ductal structures and
foci of immature cartilage embedded in loose stroma,
surrounded by solid sheets of EC cells (H and E,
x 140)
Results
Take rate oftumours
Two experiments were performed: one group of
animals was injected with 106 cells and the second
group with 5 x 106 cells. The data are presented in
Tables I and II, from which it may be seen that the
take rate depends on the site of injection and the
number of cells injected. With 106 cells per
inoculum the take rate was significantly higher (P<
0.05) in the caudal site of inoculation; moreover.
the tumours emerged earlier caudally than cranially.
The differences between the take rate in caudal and
cranial site of inoculation were not significant with
5 x 106 cells per inoculum (P<0.10) However, if
one combines the data from Tables I and II the
differences in the take rate cranially and caudally
are highly significant (r=7.1 P<0.05). It is of
interest to note that 2/30 animals injected with 106
cells did not develop tumours in either caudal or
cranial sites, whereas with 5 x 106 cells, all the
animals developed tumours at the caudal site, but
only 85 % both caudally and cranially.
Both with 106 and 5 x 106 cells per inoculum,
the caudal tumours were initially smaller than the
cranial tumours (P<0.05). Due to intragroup
variation this difference disappeared and at the end
of the experiments, there was no difference in the
size of the cranial and caudal tumours (Figures 2
and 3). In both locations the tumours grew at the
same rate and their volume increased linearly
(r values between 0.925 and 0.999).
Histological analysis
Irrespective of their size all the tumours had
essentially the same histological appearance andTRANSPLANTABLE TERATOCARCINOMA 409
Table I Take rate of tumours produced by s.c. injection of 106
teratocarcinoma cells
Days after Number ofanimals Number of tumours
inoculation at risk Observed Expected
cranial caudal cranial caudal cranial caudal
0-16 30 30 6 15 10.5 10.5
16-20 24 15 11 4 9.2 5.8
20-23 13 11 0 4 2.2 1.8
23-28 13 7 0 2 1.3 0.7
Totals 17(57%) 25(83%) 23.2 18.8
Statistical significance is determined by the log rank test for the
comparison of life tables which compares observed and expected number of
tumours under the hypothesis of equal life tables. For this table x2 = 3.7,
0.05<P<0.I0. Using the Wilcoxon or Breslow test z=2.06, P<0.05.
Table II Take rate of tumours produced by s.c. injection of 5 x 106
teratocarcinoma cells
Days after Number ofanimals Number of Tumours
inoculation at risk Observed Expected
cranial caudal cranial caudal cranial caudal
0-13 20 20 6 10 8 8
13-16 14 10 3 4 4.1 2.9
16-20 11 6 2 3 3.2 1.8
20-24 9 3 6 3 6.7 2.3
TOTALS 17(85%) 20(100%) 22 15
Log rank test: x2 = 34, 0.05<P<0.10. Breslow test: z = 1.84,
0.05<P<0.10. Combined evidence of Tables I & II, X2 = 7.1, P<0.05.
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Figure 2 Growth rate of NF- 1 tumours in cranial
and caudal sites following simultaneous inoculation
with 106 cells. The slope of the curve for cranial
tumours was 0.46 (r=0.998). The slope for the caudal
tumours was 0.50 and (r = 0.999). Statistically there is
no difference in the growth rate between the cranial
and caudal tumours. The difference in the tumour size
at 16 days is significant (P<0.05)
Time (d) after inoculation
Figure 3 Growth rate of NF-1 tumours in cranial
and caudal sites following simultaneous inoculation
with 5 x 106 cells. The slope of the curve for cranial
tumours was 0.49 (r = 0.925) and for the caudal
tumours 0.64 (r = 0.985). Statistically there is no
difference in the growth rate between the cranial and
caudal tumours. The difference in the tumour size at
13 and 16 days is significant (P<0.05).
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were composed predominantly of EC cells. With
few exceptions all the tumours contained at least 4
of the 5 somatic tissues that were considered to
indicate differentiation of cells, but these
differentiated elements rarely formed >25 % of the
tumour mass.
The morphometric analysis of the tumours in the
first experimental group confirmed the
semiquantitative estimates that there are -no
histological differences between the cranial and
caudal tumours. The differentiated tissues formed
18 + 3 % of the volume of cranial and 17 + 2 % of
the volume of the caudal tumours.
Discussion
It has been known for some time that complex
regional differences regulate the evolution of
carcinogen-induced skin tumours (Twort & Twort,
1936). Auerbach et al. (1978c) have shown that
simultaneous s.c. or i.d. injections of the same
number of neoplastic cells result in the formation of
bigger tumours in the more cranial injection site.
Regional differential growth gradients have been
reported for tumour cells i.p. injected (Morrissey et
al., 1980) as well as for dorsally transplanted
normal skin (Kubai & Auerbach, 1980). Recently,
the entire problem of regional differences in tumour
growth was reviewed by Auerbach & Auerbach
(1982).
Prompted by the reports of Auerbach et al.
(1978a, b, c) showing the differential growth rate of
both normal and tumour cells inoculated into the
cranial and caudal parts of the body we initiated
the present study in an attempt to determine
whether the differential growth rate affects the
differentiation of the developmentally-pluripotent
EC cells. However, as can be seen from our results,
the growth of NF-1 teratocarcinoma did not
conform with the predictions made on the basis of
published data (Auerbach, 1978c) and thus this
tumour could not be used for evaulating the effects
of tumour growth on stem cell differentiation.
Our observations during the first 16 days post-
inoculation are in good agreement with data of
Auerbach et al. (1978c) and suggest that during the
initial stages of tumour formation the anterior sites
provide a distinct advantage. However after the
initial period the cranial and caudal tumours
apparently grow at the same rate (slope of the
tumour growth line 0.46 vs. 0.50 and 0.49 vs. 0.64).
The slightly steeper slope of the growth line of the
caudal tumours accounts for the disappearance of
the statistically-significant differences between the
cranial and caudal tumours, although the anterior
tumours reach an average and somewhat lager size
due to the intitial growth advantage.
The initial advantage for tumour growth
provided by the anterior sites is contrasted with a
significantly higher overall tumour take in the
caudal sites. This apparent paradox cannot be
explained in terms of present day knowledge.
The reasons for the differential take rate in
caudal and cranial sites are generally not known,
but one should obviously take into consideration
various anatomical, functional, immunological
determinants that have been theoretically invoked
to explain some biological cranio-caudal differences
(Kobayashi, 1976; Auerbach et al., 1978a, b, c;
Prehn & Karnik, 1979). Our data do not allow any
speculations about the differences noted. However,
in our future studies, we plan to explore in greater
detail the immune response of the inoculated mice
in order to determine whether it could account for
the differential take rate and growth rate of
teratocarcinoma cells. Mouse EC cells do not
express antigens of the major histocompatibility
system (H-2) (Stern et al., 1975), and would thus
not be affected by cytotoxic T cells. On the other
hand, EC cells express tumour-specific antigens that
could elicit a humoral immune response (Jacob,
1977) and are also attacked by natural killer cells
(Stern et al., 1980). These antitumour defense
mechanisms could influence the take and growth
rate of tumours in different anatomical locations.
The reasons for some of the discrepancies
between the present data and those reported by
Auerbach et al. (1978c) are not clear. Since these
authors reported that another retransplantable
murine teratocarcinoma (OTT 6050) shows distinct
regional growth differences, these differences are
most likely not due to the teratocarcinomatous
nature of the present tumour. On the other hand,
one should point out that the experiments showing
a differential anterior-posterior growth rate of the
OTT 6050 teratocarcinoma were terminated 8-12
days after inoculation of tumour cells, i.e. after an
interval which corresponds to the earliest
observation periods in the present study when we
also noticed larger tumours cranially than caudally.
Thus, if comparison of our data with those
published by Auerbach et al. (1978c) were limited
to this time period there would be compatibility
between anterior and posterior tumour size. In
order to determine whether the growth of
teratocarcinomas differs in general from other
mouse tumours or whether the NF-1 tumour
represents a notable exception, the experiments with
the OTT 6050 should be prolonged to at least one
month, and other murine teratocarcinomas should
be studied in parallel.
In summary, one can state that the NF-1
teratocarcinoma inoculated simultaneously into
anterior and posterior sites shows a differentialTRANSPLANTABLE TERATOCARCINOMA 411
initial growth rate and also a differential take rate.
On the other hand, once established, the tumours
grow at the same rate in both locations. Thus our
data suggest that the regional factors, at least in
this tumour model, affect primarily the initial
establishment of the tumour.
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